Key result
Tailored factor replacement enables antithrombotic therapy for ACS and AF in hemophilia patients.
Why the study?
Patients with hemophilia have increased life expectancy and are at risk of cardiovascular diseases, but management of antithrombotic therapy in this population is challenging due to bleeding risk and lack of specific guidelines.
How should antithrombotic therapy be managed in patients with hemophilia A and B presenting with acute coronary syndromes or atrial fibrillation?
How should antithrombotic therapy be managed in patients with hemophilia A and B presenting with acute coronary syndromes or atrial fibrillation?
Antithrombotic therapy for ACS and AF in hemophilia patients requires adapting standard guidelines and tailoring coagulation factor replacement to mitigate bleeding risks.
Requires individualized antithrombotic balancing in hemophiliacs with CVD; leaves open need for prospective trials to inform guidelines.
INTRODUCTION: Patients with hemophilia now have a life expectancy very close to that of the unaffected male population and, hence, are at risk of developing the classic age-related morbidities, i.e., cardiovascular diseases. The peculiarity of the management of these diseases in hemophilia is that antithrombotic drugs impinge on the already compromised hemostasis of these lifelong bleeders. AREAS COVERED: This opinion article outlines the strategies we have developed, based on our clinical experience, for the antithrombotic treatment of two common cardiovascular diseases - acute coronary syndromes and chronic atrial fibrillation - in patients with hemophilia A and B. EXPERT OPINION: In the absence of specific evidence-based guidelines for patients with coagulation defects, antithrombotic treatment is currently based on expertise and adaptation of the guidelines developed for non-hemophilic patients. Replacement therapy should be tailored with the deficient coagulation factor so as to control the increased risk of bleeding inherent in the use of antiplatelet and anticoagulant drugs.
No takes yet. Share an insight, caveat, or question.
Pier Mannuccio Mannucci (2012) conducted a review in Acute coronary syndromes and atrial fibrillation in patients with hemophilia. Antithrombotic therapy was evaluated. Antithrombotic treatment for acute coronary syndromes and atrial fibrillation in hemophilia patients requires tailored replacement therapy to control bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: